Published in Women's Health Weekly, March 5th, 2009
"Development of inactivated H5N1 vaccines has been slow because of reluctance by US regulatory authorities to consider adjuvanted formulations and the unwillingness of Western European governments to fund vaccine trials. With effective political leadership, large amounts of live-attenuated and recombinant hemagglutinin pandemic vaccines could be produced quickly in existing facilities using egg-based technologies. New types of influenza...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly